SEINE BIO · PEPTIDE PROFILE
CJC-1295
Growth-hormone signaling research
ExperimentalGet to know the name, understand the evidence, and prepare a more informed conversation.
What is CJC-1295?
A distinct compound from ipamorelin, even when the two appear together in wellness discussions. Limited clinical data; reported serious adverse events. FDA safety context.
Explore the source
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of CJC-1295.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Overview
CJC-1295 is a growth-hormone-releasing hormone analog studied for prolonged endocrine effects. Product naming matters: the long-acting DAC compound studied in the original human trials is not interchangeable with products informally called “CJC-1295 without DAC.” Understanding that distinction helps prevent a short-acting formulation’s schedule from being attributed to a different molecule.
Community Use
PeptideDosages publishes a DAC-specific informal protocol, and Peptidepedia provides a performance-oriented profile. These publisher descriptions should retain their compound and formulation labels. A popular pairing or alias does not demonstrate that products have equivalent duration or clinical outcomes.
Doses, Durations & Cycles
Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous | No DAC: 100 mcg 2–3 times daily during weeks 1–2; 100–200 mcg 2–3 times daily during weeks 3–12 | 2–3 times daily | 12 weeks Break: 4 weeks | Published informal biohacking claim Active Bio Labs: no-DAC example |
| Subcutaneous | 100–300 mcg reported per dose; its once-daily example uses 200 mcg | Once daily in the named example | 4–6 or 8–12 weeks Break: Not stated in audited summary | Published informal biohacking claim Peptide Dosing Protocols: no-DAC example |
Important context: The numerical examples below are for products marketed as no DAC / modified GRF(1–29). CJC-1295 with DAC is longer acting and is not interchangeable.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
The chart separates human-study regimens from informal amounts. The original randomized studies measured pharmacokinetics and hormonal effects in healthy adults. Their assigned exposures are research context, not a consumer bodybuilding cycle. The table must not collapse DAC and non-DAC claims into one starting amount or maximum.
Research Findings
The two placebo-controlled studies lasted 28 and 49 days and enrolled healthy adults aged 21–61. They examined GH, IGF-1 and drug exposure. That establishes a human endocrine research signal, but the trials were not designed to prove improved athletic performance, sleep quality, injury recovery or longer healthy lifespan.
U.S. Approval & Access
The sources reviewed do not establish an FDA-approved CJC-1295 product. FDA’s compounding safety discussion identifies limited clinical data and important concerns. The lawful route for any specific product must be checked by the clinical team; an informal name, consultation or research label does not itself establish patient access.
What It Does in the Body
The studied DAC design prolongs GHRH-related activity. Its estimated half-life was 5.8–8.1 days, with GH and IGF-1 elevations lasting days after a single research exposure. Those hormonal durations are not validated onset, peak or lasting benefit for fitness or sleep goals. They also do not describe a non-DAC product’s exposure.
Benefits & Reported Experiences
The primary trials demonstrated sustained changes in hormone measurements. They did not establish a predictable gain in muscle, recovery or wellbeing, and a larger biomarker change is not automatically a better health outcome. A clinical assessment would need to consider whether the person’s actual condition calls for endocrine treatment at all.
Side Effects & Risks
FDA identifies reports including increased heart rate and systemic vasodilatory reactions, alongside immune and peptide-characterization concerns. The short early trials cannot resolve every long-term endocrine risk or combination effect. A complete assessment should consider the actual product and patient rather than repeat a small trial’s tolerability statement as universal reassurance.
Delivery Options
The original human work used subcutaneous administration of the studied molecule. That does not validate all products marketed under similar names or another route. This article supplies no preparation, injection technique or self-use regimen; the distinction between the tested substance and a marketplace alias remains part of interpreting the evidence.
Product Quality & Storage
Confirm exact identity, DAC status and formulation before discussing any claim. A certificate for a similarly named material does not establish equivalence to the trial medicine. No verified patient-use storage specification is supplied here. A lawful responsible program must provide its own product conditions instead of an assumed generic peptide shelf life.
Combinations & Interactions
CJC-1295 is frequently paired informally with ipamorelin or other secretagogues. That combination is distinct from the original CJC-1295 trial and adds separate exposure and safety questions. A shared growth-hormone theme does not supply a validated stack, and this article does not offer combination timing or a dosing ratio.
Talking With Your Provider
If fatigue, sleep, body composition or recovery is the concern, a provider can review the actual symptoms and appropriate evaluation. A hormone-related research discussion should sit within that diagnosis, not substitute for it. The goal is a supported care plan, with no guarantee of a secretagogue prescription, specific peptide or performance outcome.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
A clinician may recommend a different option—or no medication—after assessing your individual circumstances.
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Bring your curiosity. Start a conversation.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
Create a free account ↗This educational information is free to read. Create a free account to request review of your care goals. Neither an account nor paid membership guarantees a prescription, access to the named compound or research enrollment.
Educational profile · U.S. context · October 7, 2026. This page does not provide personalized medical advice, dosing, or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →